2-MERCAPTOETHANESULFONIC ACID

Summary

2-Mercaptoethanesulfonic Acid (CHEMBL1098319) is an approved small-molecule coenzyme.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 178
• Chemistry: 142.2 Da · C2H6O3S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1098319
Name	2-MERCAPTOETHANESULFONIC ACID
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	598
ChEBI	CHEBI:17905
Molecular formula	C2H6O3S2
Molecular weight	142.2
InChIKey	ZNEWHQLOPFWXOF-UHFFFAOYSA-N

SMILES: C(CS(=O)(=O)O)S

IUPAC name: 2-sulfanylethanesulfonic acid

ChEBI definition: An organosulfonic acid consisting of sulfonic acid having a 2-mercaptoethyl group attached to sulfur.

Pharmacological roles (ChEBI): coenzyme.

Also known as: Coenzyme m, Mesna free acid, MESNA, mesna

Parent form; salt/anhydrous children: CHEMBL975

Patent coverage: 2,159 distinct patent families (6,507 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 1, 3’,5’-cyclic-AMP phosphodiesterase 4A.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	6.31	AC50	485.8	nM	CHEMBL_ACT_25205013
PTGS1	6.11	AC50	779.9	nM	CHEMBL_ACT_25205946
PDE4A	5.05	AC50	8999	nM	CHEMBL_ACT_25206876

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 178.

Phase distribution

Phase	Trials
PHASE2	76
PHASE1	33
PHASE1/PHASE2	26
Not specified	18
PHASE3	15
EARLY_PHASE1	4
PHASE4	3
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01501136	PHASE4	UNKNOWN	Treatment of Natural Killer/T Cell Lymphoma-I/II
NCT01731886	PHASE4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT03172052	PHASE4	UNKNOWN	Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital
NCT04530565	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
NCT00001300	PHASE3	COMPLETED	A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma
NCT00002516	PHASE3	UNKNOWN	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing’s Sarcoma
NCT00002549	PHASE3	UNKNOWN	Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
NCT00002565	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin’s Lymphoma
NCT00002784	PHASE3	COMPLETED	High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
NCT00002802	PHASE3	COMPLETED	Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
NCT00002816	PHASE3	COMPLETED	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00002822	PHASE3	COMPLETED	Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
NCT00002875	PHASE3	COMPLETED	Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
NCT00002961	PHASE3	TERMINATED	Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
NCT00137995	PHASE3	COMPLETED	R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
NCT00177047	PHASE2/PHASE3	COMPLETED	Autologous Transplant for Multiple Myeloma
NCT01096368	PHASE3	COMPLETED	Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT01445821	PHASE3	TERMINATED	Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
NCT03342638	PHASE3	TERMINATED	Maximizing Outcome of Multiple Sclerosis Transplantation
NCT03593902	PHASE2/PHASE3	TERMINATED	Cardiac Safe Transplants for Systemic Sclerosis
NCT03829566	PHASE2/PHASE3	WITHDRAWN	Autologous Transplant To End NMO Spectrum Disorder
NCT00338377	PHASE2	ACTIVE_NOT_RECRUITING	Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
NCT00692939	PHASE1/PHASE2	RECRUITING	Autologous Stem Cell Transplantation for Crohn’s Disease
NCT01783535	PHASE2	ACTIVE_NOT_RECRUITING	Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
NCT01864109	PHASE2	ACTIVE_NOT_RECRUITING	Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
NCT01873326	PHASE2	ACTIVE_NOT_RECRUITING	Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
NCT02106988	PHASE2	ACTIVE_NOT_RECRUITING	Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
NCT02436707	PHASE2	ACTIVE_NOT_RECRUITING	Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02790515	PHASE2	ACTIVE_NOT_RECRUITING	Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
NCT03573700	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
NCT03577431	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Liver Transplantation With Tregs at MGH
NCT03630211	PHASE2	RECRUITING	Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT03663933	PHASE2	ACTIVE_NOT_RECRUITING	Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
NCT03821610	PHASE2	ACTIVE_NOT_RECRUITING	A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
NCT03849651	PHASE2	ACTIVE_NOT_RECRUITING	TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
NCT04224558	PHASE1/PHASE2	RECRUITING	Stem Cell Transplantation in Crohn’s Disease
NCT04558736	PHASE2	RECRUITING	Haploidentical HCT for Severe Aplastic Anemia
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04904588	PHASE2	ACTIVE_NOT_RECRUITING	HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04959175	PHASE1/PHASE2	RECRUITING	Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).